Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | RB1 | P06400 | 7/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10764787 | 0.84 | BRD3 (0.55) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL10764800 | 0.84 | BRD3 (0.55) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL13751063 | 0.81 | BRD3 (0.61) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL6924595 | 0.79 | GRIN2B (0.59) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL5473259 | 0.77 | RB1 (0.61) | BRD3RB1SIRT1SIRT2CYP2D6 | |
| SCHEMBL13751061 | 0.77 | BRD3 (0.56) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL18085037 | 0.77 | BRD3 (0.56) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL832934 | 0.77 | SIRT1 (0.60) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL12159018 | 0.76 | BRD3 (0.55) | BRD3RB1SIRT1SIRT2HTR7 | |
| SCHEMBL10754574 | 0.76 | BRD3 (0.55) | BRD3RB1SIRT1SIRT2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1849307-B | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists | LILLY CO ELI | 2011-08-03 | — | — | CN | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| CN-100352817-C | Pyridinoylpiperidines as 5-HTLF agonists | LILLY CO ELI (US) | 2007-12-05 | — | — | CN | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
| CN-1849307-A | As 5-HT1FSubstituted 2-carbonylamino-6-agonistsPiperidinylaminopyridines and substituted 1-carbonylamino-3-piperidinylaminophenyls | LILLY CO ELI (US) | 2006-10-18 | — | — | CN | disclosed |
| CN-1642939-A | As 5-HT1FPyridylpiperidines as agonists | LILLY CO ELI (US) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | HTR1F, HTR1A, HTR3B | BRD3 1756/4885RB1 4113/4885SIRT1 1534/4885 |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | HTR1F, HTR1A, HTR3B | BRD3 1756/4885RB1 4113/4885SIRT1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.